Evaluation of the Sensitivity, Specificity, and Utility of the Reveal® TP (Syphilis) Antibody POCT
Evaluation of the Sensitivity, Specificity, and Utility of the Reveal® TP (Syphilis) Antibody POCT to Diagnose Infectious Syphilis in Participants Attending the BCCDC's STI Clinic in Vancouver, BC
Sponsor: MedMira Laboratories Inc.
A NA clinical study on Early Syphilis, Symptomatic and Syphilis, this trial is completed. The trial is conducted by MedMira Laboratories Inc. and has accumulated 6 data snapshots since 2023. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
6 versions recorded-
Feb 2026 — Present [monthly]
Completed NA
Status: Active Not Recruiting → Completed
-
Oct 2025 — Feb 2026 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Sep 2024 — Oct 2025 [monthly]
Recruiting NA
-
Jul 2024 — Sep 2024 [monthly]
Recruiting NA
-
Nov 2023 — Jul 2024 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
▶ Show 1 earlier version
-
May 2023 — Nov 2023 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- MedMira Laboratories Inc.
- Public Health Agency of Canada (PHAC)
For direct contact, visit the study record on ClinicalTrials.gov .